Anthera Pharmaceuticals, Inc. (ANTH)
| Market Cap | 634,153 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.93M |
| Shares Out | 22.17M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 5 |
| Last Price | $0.0757 |
| Previous Close | $0.0800 |
| Change ($) | -0.0043 |
| Change (%) | -5.38% |
| Day's Open | 0.0640 |
| Day's Range | 0.0640 - 0.0757 |
| Day's Volume | 28,134 |
| 52-Week Range | 0.0100 - 0.1900 |
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which to...
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged following...
About ANTH
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more...]
| Industry Biotechnology | IPO Date Mar 1, 2010 |
| CEO J. Craig Thompson | Employees 21 |
| Stock Exchange OTCMKTS | Ticker Symbol ANTH |